Crossmark

Serum 5’-tiRNA-iMet-CAT is a novel biomarker for the diagnosis and early postoperative assessment of hepatocellular carcinoma

Published Online: 2026-07-07

Authors

Hong, Yan

Qin, Shiyi

Li, Xian

Ding, Rui

Ju, Shaoqing https://orcid.org/0000-0001-7448-2020
Funding

Funding for this research was provided by:

This project was supported by grants from the Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX25_3807)

This project was supported by grants from the Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX24_3582)

the National Natural Science Foundation of China (No. 82472356, No. 82272411)

the Jiangsu Province Medical Key Discipline (ZDXK202240)

Science and Technology Project of Jiangsu Province (BE2023741)

Foundation of Jiangsu Province Research Hospital (YJXYY202204-XKB16)
License Information

Text and Data Mining valid from 2026-07-07

Version of Record valid from 2026-09-30
More Information

Article History

Received: 24 November 2025

Accepted: 28 June 2026

First Online: 7 July 2026

Declarations

Ethics approval and consent to participate: This study conformed to the Helsinki Declaration principles, and the local hospital ethics committee approved the study (Ethical Review Report No. 2018-L055).

Consent for publication: Not applicable.

Competing interests: The authors declare no competing interests.

Document is current